Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Aggressive Lymphoma
  • CLL
  • DLBCL
  • Follicular Lymphoma
  • Indolent Lymphoma
  • Marginal Zone Lymphoma
  • MCL
  • Mediastinal Large B Cell Lymphoma
  • Richter's Transformation
  • SLL
Type
Interventional
Phase
Phase 1
Design
Allocation: Non-RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: This is a Phase Ib open-label, multi-center, dose-finding study. Once a single-agent dose level is declared safe, the study will evaluate sequentially higher doses of TG-1801 in combination with ublituximab.Masking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

Not Provided

Not Provided

Tracking Information

NCT #
NCT04806035
Collaborators
Not Provided
Investigators
Not Provided